IZOTROPIC CORP. Net Assets
IZOTROPIC CORP. net assets. Based on the latest financial reports, IZOTROPIC CORP. (1R3) has net assets worth €-5.63 Million EUR (≈ $-6.58 Million USD) as of April 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€439.78K ≈ $514.15K USD) and total liabilities (€6.06 Million ≈ $7.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore IZOTROPIC CORP. (1R3) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-5.63 Million |
| % of Total Assets | -1279.05% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of IZOTROPIC CORP. (2022–2026)
Net assets of IZOTROPIC CORP. from 2022 to 2026. This chart illustrates how IZOTROPIC CORP.'s net assets have evolved over time, based on quarterly financial data. See net asset quality index of IZOTROPIC CORP. to measure how much of total assets are equity-financed.
Annual Net Assets for IZOTROPIC CORP. (2022–2026)
The table below shows the annual net assets of IZOTROPIC CORP. from 2022 to 2026. For live market cap and overall valuation, see IZOTROPIC CORP. stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2026-04-30 | €-5.63 Million ≈ $-6.58 Million |
-15.76% |
| 2025-04-30 | €-4.86 Million ≈ $-5.68 Million |
-26.33% |
| 2024-04-30 | €-3.85 Million ≈ $-4.50 Million |
-25.13% |
| 2023-04-30 | €-3.07 Million ≈ $-3.59 Million |
-720.57% |
| 2022-04-30 | €-374.59K ≈ $-437.93K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to IZOTROPIC CORP.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1031678400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
IZOTROPIC CORP. Net Assets Breakdown (April 2026)
IZOTROPIC CORP. net assets breakdown by equity component as of April 2026.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €18.67 Million | % |
| Total Equity | €-5.63 Million | 100.00% |
IZOTROPIC CORP. Competitors by Market Cap
The table below lists competitors of IZOTROPIC CORP. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bulletin Resources Ltd
AU:BNR
|
$6.44 Million |
|
Masonglory Limited Ordinary Shares
NASDAQ:MSGY
|
$6.44 Million |
|
Sewon E&C
KO:091090
|
$6.45 Million |
|
Immuron Ltd ADR
NASDAQ:IMRN
|
$6.45 Million |
|
Activeport Group Ltd
AU:ATV
|
$6.44 Million |
|
Natural Health Trend
NASDAQ:NHTC
|
$6.43 Million |
|
Postmedia Network Canada Corp
TO:PNC-B
|
$6.43 Million |
|
Max Resource Corp
V:MAX
|
$6.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IZOTROPIC CORP.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from -4,858,987 to -5,625,001, a change of -766,014.
- Net loss of 2,184,633 reduced equity.
- New share issuances of 664,453 increased equity.
- Other factors increased equity by 754,166.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-2.18 Million | -38.84% |
| Share Issuances | €664.45K | +11.81% |
| Other Changes | €754.17K | +13.41% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares IZOTROPIC CORP.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-04-30 | €-0.01 | €0.08 | x |
| 2023-04-30 | €-0.06 | €0.08 | x |
| 2024-04-30 | €-0.07 | €0.08 | x |
| 2025-04-30 | €-0.08 | €0.08 | x |
| 2026-04-30 | €-0.08 | €0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IZOTROPIC CORP. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-6.62 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-5.35 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.18 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | €-2.65 Million |
| 2026 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.62 Million |
Industry Comparison
This section compares IZOTROPIC CORP.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $4,195,243,572
- Average return on equity (ROE) among peers: -536.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IZOTROPIC CORP. (1R3) | €-5.63 Million | 0.00% | N/A | $6.44 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $10.41 Million | -90.99% | 0.83x | $839.64K |
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | $24.45 Billion | 8.28% | 0.21x | $610.33 Million |
| Check-Cap Ltd (7CC) | $10.41 Million | -84.81% | 0.18x | $9.20 Million |
| INTERGRATED DIA.H DL 025 (8I8) | $2.45 Billion | 22.11% | 1.16x | $246.03 Million |
| GENETIC ANALYSIS NK -60 (8V8) | $27.08 Million | -42.15% | 0.94x | $2.36 Million |
| GENINCODE PLC LS -01 (9PL) | $124.00K | -4600.81% | 18.17x | $5.28 Million |
| INOVIQ LTD. (EGQ0) | $19.62 Million | -45.73% | 0.10x | $12.59 Million |
| Eurofins Scientific SE (ESF0) | $2.72 Billion | 8.23% | 1.65x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $8.07 Billion | 1.90% | 1.16x | $7.52 Billion |
About IZOTROPIC CORP.
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. It develops and commercializes IzoView, a breast CT imaging system. The company was incorporated in 2016 and is headquartered in Surrey, Canada.